University of Michigan

Acceleron Pharma Inc.

Benjamin Levi

Shailesh Agarwal

Ravindra Kumar

Michael D Morris

Omer Berenfeld

In part, the present disclosure relates methods for treating heterotopic ossification or one or more complications of heterotopic ossification. In particular, the disclosure provided methods for treating heterotopic ossification by administering to a patient in need thereof one or more TGFβ antagonists, optionally in combination with one or more additional active agents or supportive therapies for treating heterotopic ossification. For example, in some embodiments, the disclosure provided methods for treating heterotopic ossifications by administering to a patient in need thereof an effective amount of a TβRII polypeptide.

Methods for treating heterotopic ossification

A short wave infrared (SWIR) imaging system and method of using the same is provided for assessing a tissue damage depth and/or readiness for reconstruction and/or debridement. The SWIR imaging system includes a light source for illuminating the wound or burn, an image light-registering camera system having at least one narrow-band SWIR filter to image the wound or burn and output imaging information, and a detection system for receiving the imaging information and processing the imaging information to determine a tissue damage depth and/or readiness for reconstruction and/or debridement assessment.

Short wave infrared bedside or intra operative assessment of wound or burn depth at dry-wet layers and readiness for reconstruction

The invention provides a method of treating heterotopic ossification in a subject in need thereof. The method comprises administering a hypoxia inducible factor-1&#x3b1; (Hif-1&#x3b1;) inhibitor to the subject. In various embodiments, the Hif-1&#x3b1; inhibitor is PX-478, rapamycin, or digoxin.

Growing community of inventors

Ann Arbor, MI, United States of America

Benjamin Levi